NR 565 Midterm Exam Prep Document | 2026/2027 Edition |
250 Verified Questions
NR 565 Advanced Pharmacology Midterm Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED
A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive study resource provides 250 verified questions and answers for the NR 565
Advanced Pharmacology Midterm Exam, tailored to the 2026/2027 academic year. It covers essential
pharmacological principles, drug classifications, and clinical applications, ensuring thorough
preparation. Each question is accompanied by a detailed rationale to reinforce understanding and
promote retention. Designed for Chamberlain University students, this document guarantees a pass
when used diligently.
Key Features:
Pharmacokinetics and Pharmacodynamics
Autonomic and Cardiovascular Pharmacology
Neurological and Psychiatric Pharmacotherapy
Endocrine and Metabolic Disorders
Antimicrobial and Anti-inflammatory Agents
Special Populations and Safety Considerations
Updates for 2026:
- Updated to reflect 2026/2027 NR 565 curriculum changes
- Incorporated latest clinical guidelines and FDA approvals
- Enhanced rationales with evidence-based explanations
- Added new questions on emerging pharmacotherapies
- Revised answer explanations for clarity and accuracy
Abstract:
The NR 565 Midterm Exam is a critical assessment of advanced pharmacological knowledge, requiring a deep
understanding of drug mechanisms, therapeutic uses, adverse effects, and patient-specific considerations. This
document compiles 250 meticulously selected questions that mirror the exam's scope and difficulty, covering key
areas such as pharmacokinetics, drug interactions, and pharmacogenomics. Each question is paired with a
comprehensive answer and rationale, facilitating active learning and self-assessment. The content is aligned with
the latest 2026/2027 guidelines, ensuring relevance and accuracy. By engaging with this material, students will
solidify their grasp of complex pharmacological concepts and enhance their clinical reasoning skills. This resource
is an indispensable tool for achieving a high score and demonstrating mastery in advanced pharmacology.
Keywords:
NR 565, Advanced Pharmacology, Midterm Exam, Chamberlain University, Verified Questions, 2026/2027,
Pharmacology Review, Graded A+
Answer Format:
Each question is presented in a multiple-choice format, followed by the correct answer and a detailed rationale
explaining why it is correct and why the other options are incorrect. Rationales include clinical context, mechanism
of action, and relevant guidelines to enhance comprehension.
Compliance Checklist:
Aligned with Chamberlain University NR 565 course objectives
Updated to 2026/2027 academic standards
Includes evidence-based rationales for every answer
Page 1
, Covers all major drug classes and therapeutic areas
Suitable for self-study and exam review
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-40 Absorption, Distribution, Metabolism, 16%
Pharmacodynamics Excretion, Drug-Receptor Interactions
Autonomic and Cardiovascular 41-80 Adrenergic Agonists/Antagonists, 16%
Pharmacology Cholinergic Agents, Antihypertensives,
Antiarrhythmics, Anticoagulants
Neurological and Psychiatric 81-120 Antiepileptics, Antidepressants, 16%
Pharmacotherapy Antipsychotics, Anxiolytics, Opioid
Analgesics
Endocrine and Metabolic 121-160 Insulin and Oral Hypoglycemics, Thyroid 16%
Disorders Hormones, Corticosteroids, Osteoporosis
Agents
Antimicrobial and 161-200 Antibiotics, Antivirals, Antifungals, 16%
Anti-inflammatory Agents NSAIDs, DMARDs
Special Populations and Safety 201-250 Pediatrics, Geriatrics, Pregnancy/Lactation, 20%
Considerations Renal/Hepatic Impairment, Drug
Interactions
Page 2
,Q1. A patient with chronic kidney disease (eGFR 25 mL/min) and type 2 diabetes has
persistent hyperglycemia despite metformin and insulin glargine. Which
pharmacodynamic principle most accurately justifies adding an SGLT2 inhibitor?
A. SGLT2 inhibitors increase insulin secretion from pancreatic beta cells.
B. SGLT2 inhibitors lower glucose reabsorption threshold independent of insulin,
reducing HbA1c and conferring renoprotection.
C. SGLT2 inhibitors are contraindicated in CKD due to increased risk of lactic acidosis.
D. SGLT2 inhibitors primarily act on hepatic gluconeogenesis to reduce glucose
output.
Correct Answer: B. SGLT2 inhibitors lower glucose reabsorption threshold
independent of insulin, reducing HbA1c and conferring renoprotection.
Rationale: SGLT2 inhibitors reduce renal glucose reabsorption, lowering plasma glucose
without depending on insulin secretion or action. They also have favorable renal
outcomes, making them appropriate even in CKD (eGFR >25). Option A describes
sulfonylureas, C is outdated (they are beneficial), and D is incorrect as their primary
action is renal.
Why Wrong:
A - Increases insulin secretion is the mechanism of sulfonylureas, not SGLT2
inhibitors.
C - SGLT2 inhibitors are not contraindicated in CKD; they offer renoprotective
benefits.
D - Inhibiting hepatic gluconeogenesis is not the primary mechanism of SGLT2
inhibitors.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 45
Q2. A patient on warfarin with a therapeutic INR of 2.5 is prescribed a course of
metronidazole for an anaerobic infection. What is the most critical pharmacokinetic
interaction and the recommended management?
A. Metronidazole inhibits CYP2C9, increasing warfarin levels; reduce warfarin dose
and monitor INR every 3-4 days.
B. Metronidazole induces CYP3A4, decreasing warfarin levels; increase warfarin dose.
C. Metronidazole displaces warfarin from albumin, causing transient free warfarin
increase; no dose adjustment needed.
D. Metronidazole increases vitamin K absorption, reducing warfarin effect; supplement
vitamin K.
Correct Answer: A. Metronidazole inhibits CYP2C9, increasing warfarin levels;
reduce warfarin dose and monitor INR every 3-4 days.
Rationale: Metronidazole is a potent inhibitor of CYP2C9, the primary enzyme that
metabolizes the S-enantiomer of warfarin. This leads to increased warfarin concentrations
Page 3
, and INR, requiring dose reduction and close INR monitoring. Option B is wrong because
metronidazole is an inhibitor, not an inducer. C is a theoretical protein-binding interaction
that is rarely clinically significant. D is incorrect; metronidazole does not affect vitamin K
absorption.
Why Wrong:
B - Metronidazole inhibits, not induces, CYP2C9, leading to increased warfarin effect.
C - Protein-binding displacement is transient and not clinically significant with
warfarin.
D - Metronidazole does not increase vitamin K absorption; it potentiates warfarin.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 45
Q3. A patient with heart failure with reduced ejection fraction (HFrEF) is on
sacubitril/valsartan. The provider considers adding spironolactone. Which laboratory
monitoring is essential before and during therapy to prevent a life-threatening
adverse effect?
A. Serial B-type natriuretic peptide (BNP) levels to guide dosing.
B. Monitoring serum potassium and renal function, given the additive hyperkalemia
risk with sacubitril/valsartan.
C. Liver function tests due to hepatotoxicity.
D. Serum digoxin levels to avoid toxicity.
Correct Answer: B. Monitoring serum potassium and renal function, given the
additive hyperkalemia risk with sacubitril/valsartan.
Rationale: Both sacubitril/valsartan (via angiotensin receptor blockade) and
spironolactone (a mineralocorticoid receptor antagonist) increase serum potassium.
Combining them raises the risk of severe hyperkalemia. Monitoring potassium and renal
function is essential. BNP is used for HF status, not for drug safety. Liver toxicity is not a
primary concern, and digoxin levels are irrelevant unless the patient is on digoxin.
Why Wrong:
A - BNP monitoring guides heart failure management but does not prevent
hyperkalemia.
C - Neither sacubitril/valsartan nor spironolactone is primarily hepatotoxic.
D - Digoxin levels are only relevant if the patient is on digoxin, not for this
combination.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 35
Q4. A patient is prescribed an ACE inhibitor for hypertension. Which of the
following best explains why this class is preferred over an ARB in patients with
post-myocardial infarction (MI) with left ventricular dysfunction?
A. ACE inhibitors are more effective at lowering blood pressure than ARBs.
Page 4
250 Verified Questions
NR 565 Advanced Pharmacology Midterm Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED
A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive study resource provides 250 verified questions and answers for the NR 565
Advanced Pharmacology Midterm Exam, tailored to the 2026/2027 academic year. It covers essential
pharmacological principles, drug classifications, and clinical applications, ensuring thorough
preparation. Each question is accompanied by a detailed rationale to reinforce understanding and
promote retention. Designed for Chamberlain University students, this document guarantees a pass
when used diligently.
Key Features:
Pharmacokinetics and Pharmacodynamics
Autonomic and Cardiovascular Pharmacology
Neurological and Psychiatric Pharmacotherapy
Endocrine and Metabolic Disorders
Antimicrobial and Anti-inflammatory Agents
Special Populations and Safety Considerations
Updates for 2026:
- Updated to reflect 2026/2027 NR 565 curriculum changes
- Incorporated latest clinical guidelines and FDA approvals
- Enhanced rationales with evidence-based explanations
- Added new questions on emerging pharmacotherapies
- Revised answer explanations for clarity and accuracy
Abstract:
The NR 565 Midterm Exam is a critical assessment of advanced pharmacological knowledge, requiring a deep
understanding of drug mechanisms, therapeutic uses, adverse effects, and patient-specific considerations. This
document compiles 250 meticulously selected questions that mirror the exam's scope and difficulty, covering key
areas such as pharmacokinetics, drug interactions, and pharmacogenomics. Each question is paired with a
comprehensive answer and rationale, facilitating active learning and self-assessment. The content is aligned with
the latest 2026/2027 guidelines, ensuring relevance and accuracy. By engaging with this material, students will
solidify their grasp of complex pharmacological concepts and enhance their clinical reasoning skills. This resource
is an indispensable tool for achieving a high score and demonstrating mastery in advanced pharmacology.
Keywords:
NR 565, Advanced Pharmacology, Midterm Exam, Chamberlain University, Verified Questions, 2026/2027,
Pharmacology Review, Graded A+
Answer Format:
Each question is presented in a multiple-choice format, followed by the correct answer and a detailed rationale
explaining why it is correct and why the other options are incorrect. Rationales include clinical context, mechanism
of action, and relevant guidelines to enhance comprehension.
Compliance Checklist:
Aligned with Chamberlain University NR 565 course objectives
Updated to 2026/2027 academic standards
Includes evidence-based rationales for every answer
Page 1
, Covers all major drug classes and therapeutic areas
Suitable for self-study and exam review
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-40 Absorption, Distribution, Metabolism, 16%
Pharmacodynamics Excretion, Drug-Receptor Interactions
Autonomic and Cardiovascular 41-80 Adrenergic Agonists/Antagonists, 16%
Pharmacology Cholinergic Agents, Antihypertensives,
Antiarrhythmics, Anticoagulants
Neurological and Psychiatric 81-120 Antiepileptics, Antidepressants, 16%
Pharmacotherapy Antipsychotics, Anxiolytics, Opioid
Analgesics
Endocrine and Metabolic 121-160 Insulin and Oral Hypoglycemics, Thyroid 16%
Disorders Hormones, Corticosteroids, Osteoporosis
Agents
Antimicrobial and 161-200 Antibiotics, Antivirals, Antifungals, 16%
Anti-inflammatory Agents NSAIDs, DMARDs
Special Populations and Safety 201-250 Pediatrics, Geriatrics, Pregnancy/Lactation, 20%
Considerations Renal/Hepatic Impairment, Drug
Interactions
Page 2
,Q1. A patient with chronic kidney disease (eGFR 25 mL/min) and type 2 diabetes has
persistent hyperglycemia despite metformin and insulin glargine. Which
pharmacodynamic principle most accurately justifies adding an SGLT2 inhibitor?
A. SGLT2 inhibitors increase insulin secretion from pancreatic beta cells.
B. SGLT2 inhibitors lower glucose reabsorption threshold independent of insulin,
reducing HbA1c and conferring renoprotection.
C. SGLT2 inhibitors are contraindicated in CKD due to increased risk of lactic acidosis.
D. SGLT2 inhibitors primarily act on hepatic gluconeogenesis to reduce glucose
output.
Correct Answer: B. SGLT2 inhibitors lower glucose reabsorption threshold
independent of insulin, reducing HbA1c and conferring renoprotection.
Rationale: SGLT2 inhibitors reduce renal glucose reabsorption, lowering plasma glucose
without depending on insulin secretion or action. They also have favorable renal
outcomes, making them appropriate even in CKD (eGFR >25). Option A describes
sulfonylureas, C is outdated (they are beneficial), and D is incorrect as their primary
action is renal.
Why Wrong:
A - Increases insulin secretion is the mechanism of sulfonylureas, not SGLT2
inhibitors.
C - SGLT2 inhibitors are not contraindicated in CKD; they offer renoprotective
benefits.
D - Inhibiting hepatic gluconeogenesis is not the primary mechanism of SGLT2
inhibitors.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 45
Q2. A patient on warfarin with a therapeutic INR of 2.5 is prescribed a course of
metronidazole for an anaerobic infection. What is the most critical pharmacokinetic
interaction and the recommended management?
A. Metronidazole inhibits CYP2C9, increasing warfarin levels; reduce warfarin dose
and monitor INR every 3-4 days.
B. Metronidazole induces CYP3A4, decreasing warfarin levels; increase warfarin dose.
C. Metronidazole displaces warfarin from albumin, causing transient free warfarin
increase; no dose adjustment needed.
D. Metronidazole increases vitamin K absorption, reducing warfarin effect; supplement
vitamin K.
Correct Answer: A. Metronidazole inhibits CYP2C9, increasing warfarin levels;
reduce warfarin dose and monitor INR every 3-4 days.
Rationale: Metronidazole is a potent inhibitor of CYP2C9, the primary enzyme that
metabolizes the S-enantiomer of warfarin. This leads to increased warfarin concentrations
Page 3
, and INR, requiring dose reduction and close INR monitoring. Option B is wrong because
metronidazole is an inhibitor, not an inducer. C is a theoretical protein-binding interaction
that is rarely clinically significant. D is incorrect; metronidazole does not affect vitamin K
absorption.
Why Wrong:
B - Metronidazole inhibits, not induces, CYP2C9, leading to increased warfarin effect.
C - Protein-binding displacement is transient and not clinically significant with
warfarin.
D - Metronidazole does not increase vitamin K absorption; it potentiates warfarin.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 45
Q3. A patient with heart failure with reduced ejection fraction (HFrEF) is on
sacubitril/valsartan. The provider considers adding spironolactone. Which laboratory
monitoring is essential before and during therapy to prevent a life-threatening
adverse effect?
A. Serial B-type natriuretic peptide (BNP) levels to guide dosing.
B. Monitoring serum potassium and renal function, given the additive hyperkalemia
risk with sacubitril/valsartan.
C. Liver function tests due to hepatotoxicity.
D. Serum digoxin levels to avoid toxicity.
Correct Answer: B. Monitoring serum potassium and renal function, given the
additive hyperkalemia risk with sacubitril/valsartan.
Rationale: Both sacubitril/valsartan (via angiotensin receptor blockade) and
spironolactone (a mineralocorticoid receptor antagonist) increase serum potassium.
Combining them raises the risk of severe hyperkalemia. Monitoring potassium and renal
function is essential. BNP is used for HF status, not for drug safety. Liver toxicity is not a
primary concern, and digoxin levels are irrelevant unless the patient is on digoxin.
Why Wrong:
A - BNP monitoring guides heart failure management but does not prevent
hyperkalemia.
C - Neither sacubitril/valsartan nor spironolactone is primarily hepatotoxic.
D - Digoxin levels are only relevant if the patient is on digoxin, not for this
combination.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 35
Q4. A patient is prescribed an ACE inhibitor for hypertension. Which of the
following best explains why this class is preferred over an ARB in patients with
post-myocardial infarction (MI) with left ventricular dysfunction?
A. ACE inhibitors are more effective at lowering blood pressure than ARBs.
Page 4
